(1)Drawbacks of oral smaglutide Gastrointestinal discomfort is more common The oral version of semaglutide may cause gastrointestinal discomfort, such as nausea, vomiting, abdominal pain, constipation, etc
34 SGLT-2 inhibitors Since SGLT-2 activity accounts for the majority of glucose reabsorption in the kidney, inhibition of SGLT-2 effectively blocks the reabsorption of filtered glucose, leading to a pharmacologically augmented glucosuria
Combining them can lead to severe gastrointestinal distress and dehydration
This GLP-1R plus strategy, combining GLP-1 RAs with other hormone-based medications that target different pathways, such as amylin or GIP, may result in additive or synergistic effects that enhance weight loss and improve metabolic outcomes
Examples of GLP-1 drugs include the following: Historically, FDA did not approve GLP-1 drugs for weight loss